Skyline Therapeutics’ Novel Gene Therapy SKG1108 Receives FDA Orphan Drug Designation for Retinitis Pigmentosa
BOSTON and SHANGHAI, Sept. 3, 2024 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SKG1108, a novel one-time intravitreally delivered gene therapy for the treatment of Retinitis Pigmentosa (RP). This designation...
QingSong Health Chairman Speaks at Global Ethics Forum in Geneva: Advancing Ethical Leadership in Healthcare
GENEVA, Sept. 3, 2024 /PRNewswire/ -- At the Global Ethics Forum, a leading platform that convenes stakeholders from various sectors to discuss peace, sustainability, and ethical leadership, the Chairman of QingSong Health, China's premier healthcare solutions technology platform, delivered a compelling keynote address. The Forum serves as a multisectoral space for dialogue among institutions, policymakers, and experts, aimed at envisioning...
GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA
Co-development of innovative new drug for the treatment of Fabry disease as "the world's first once-monthly subcutaneous treatment" Improves efficacy compared to existing treatment for kidney function, vascular disease, and peripheral nerve disorders YONGIN, South Korea, Sept. 3, 2024 /PRNewswire/ -- GC Biopharma announced that its collaborative project for Fabry treatment...
Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum’s Disease
NEW TAIPEI CITY, Sept. 3, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the subject recruitment of CBL-514 Phase 2b study for Dercum's disease (CBL-0202 DD Phase 2b study, NCT06303570) has been initiated. The study results are anticipated in Q4 2025. CBL-0202DD study is a randomized, placebo-controlled Phase 2b study evaluating CBL-514...
Ensuring Safe Drinking Water: A Closer Look at the Hidden Risks in Bottled Water
JAKARTA, Indonesia, Sept. 3, 2024 /PRNewswire/ -- NGO Sirkadian, focusing on public health and environmental advocacy, recently discussed with Prof. Yuni K. Krisnandi, M.Sc., Ph.D., an inorganic chemistry expert and a member of the Royal Society of Chemistry, the growing concerns over the health risks of bottled water consumption. Prof. Yuni highlighted hidden dangers in bottled water that could...
Asia Pacific Enterprise Awards 2024 Regional Edition Honors Champions of Inclusive Entrepreneurship Across Asia
SINGAPORE, Sept. 2, 2024 /PRNewswire/ -- The Asia Pacific Enterprise Awards (APEA) 2024 Regional Edition proudly celebrates the entrepreneurial spirit, honoring a new elite of industry leaders spearheading inclusive entrepreneurship across Asia. Set in Bangkok, Thailand, this year's awards highlighted leading business leaders and enterprises who have championed inclusivity, broken barriers for underrepresented groups, and created pathways for individuals...
Neusoft Education Actively Advances Education-Healthcare-Wellness Integrated Development, Starting a New Horizon for High-Quality Development
HONG KONG, Aug. 29, 2024 /PRNewswire/ -- Neusoft Education Technology Co. Limited (Stock code: 9616.HK, "Neusoft Education" or "the Group") announced its interim results for 2024. In 2024, the Group strategically expanded its elderly education and healthcare and wellness services on the basis of its existing "One Fundamental Business with Two Strategic Businesses" business system, and entered into a new...
Seegene and Springer Nature Launch ‘Nature Awards MDx Impact Grants’ to Innovate Syndromic PCR Diagnostic Assays
- Nature Awards MDx Impact Grants in partnership with Seegene extends commitment to external innovation.- Global research teams invited to submit proposals to develop new tests for human infectious diseases. Application deadline: December 2, 2024.- Nature Awards to lead the application and evaluation process. Projects selected in August 2025 based on...
Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor
NANJING, China, Sept. 2, 2024 /PRNewswire/ -- On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration agreement with Shenzhen TargetRx Inc. The partnership focuses on the ALK/ROS1 dual receptor tyrosine kinase inhibitor TGRX-326, a clinical-stage anti-tumor candidate. According to the terms of the agreement, Simcere Zaiming will acquire exclusive commercial rights...
OrionStar Robotics Launches CarryBot: The World’s First Logistics Robot for Micro-Fulfillment Centers
BEIJING, Sept. 2, 2024 /PRNewswire/ -- OrionStar Robotics, the global innovator in service robot applications, has launched CarryBot, the world's first logistics robot designed specifically for Micro-Fulfillment Centers (MFCs). MFCs are small, highly automated warehouses located in urban areas or close to consumers, aimed at shortening order response times and enhancing customer satisfaction. CarryBot is engineered to meet the...
